SNWV (SANUWAVE Health) Long-Term Debt: $14.99 Mil (As of Mar. 2026)


SNWV SANUWAVE Health Inc SNWV
38 GF Score
Price $11.71
GF Value $12.02
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is SANUWAVE Health Long-Term Debt?

SANUWAVE Health SNWV -3.43% 38 Long-Term Debt is $14.99 Mil as of Mar. 2026. GuruFocus rates SNWV with a GF Score™ of 38/100 and a GF Value™ of $12.02 (Fairly Valued). The stock has 8 warning signs investors should review.

SANUWAVE Health's Long-Term Debt for the quarter that ended in Mar. 2026 was $14.99 Mil.

SANUWAVE Health's quarterly Long-Term Debt declined from Sep. 2025 ($17.73 Mil) to Dec. 2025 ($16.32 Mil) and declined from Dec. 2025 ($16.32 Mil) to Mar. 2026 ($14.99 Mil).

SANUWAVE Health's annual Long-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($16.32 Mil).

SANUWAVE Health  (NAS:SNWV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

SANUWAVE Health Long-Term Debt Related Terms

SANUWAVE Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for SANUWAVE Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SANUWAVE Health Long-Term Debt Chart

SANUWAVE Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.00 0.00 0.00 16.32

SANUWAVE Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 17.73 16.32 14.99
SNWV
38GF Score
SANUWAVE Health Inc SNWV
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $14.99 Mil mean?
SANUWAVE Health (SNWV) has a Long-Term Debt of $14.99 Mil as of Mar. 2026.
Is SANUWAVE Health's Long-Term Debt too high?
SANUWAVE Health's current Long-Term Debt is $14.99 Mil. Overall, SANUWAVE Health has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's Long-Term Debt compare to RTGN and NNOX?
SANUWAVE Health's Long-Term Debt of $14.99 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. SANUWAVE Health's current Long-Term Debt is $14.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Fairly Valued. The stock's GF Value™ is $12.02, compared to a current price of $11.71 — trading 2.6% below its estimated fair value. The current Long-Term Debt is $14.99 Mil. SANUWAVE Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current Long-Term Debt is $14.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SANUWAVE Health (SNWV) Overvalued in 2026?

Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued. The current stock price of $11.71 is trading 2.6% below its estimated GF Value™ of $12.02. GuruFocus considers SANUWAVE Health to be Fairly Valued.

Key valuation signals for SNWV:

  • Long-Term Debt: $14.99 Mil
  • GF Value™: $12.02 vs. price of $11.71 (2.6% below fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SANUWAVE Health Business Description

Address 9600 W. 76th Street, Suite 118, Eden Prairie, MN, USA, 55344
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
38GF Score

Get the complete analysis for SNWV

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.71
Price
$12.02
GF Value